Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Keratosis, Actinic 10Condylomata Acuminata 3Virus Diseases 1Usual Type Vulval Intraepithelial Neoplasia (uVIN) 1Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Sexually Transmitted Diseases 1Papillomavirus Infections 1Non-Muscle Invasive Bladder Neoplasms 1Non-Melanoma Skin Cancers 1Neoplasms 1Lymphoma, Follicular 1Keratosis, Seborrheic 1Exanthema 1Carcinoma, Non-Small-Cell Lung 1Acne Vulgaris 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 3valrubicin 1ledipasvir, sofosbuvir drug combination 1hepatitis C immune globulin, human 1halofantrine 1VP-102 1Therapies, Investigational 1Papillomavirus Vaccines 1Oncolytic Virotherapy 1Mitomycin 1Ipilimumab 1Interferons 1Influenza Vaccines 1Immunoglobulin G 1Imiquimod 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Gemcitabine 1Gels 1Drug Therapy 1Cantharidin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Virus Diseases × Gels × Clear all
NCT02724254 2018-07-20

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients

Vaxart

Phase 2 Completed
218 enrolled

Condylomata Acuminata, Sexually Transmitted Diseases, Virus Diseases, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡